Clinical trials: Patients With Advanced Solid Tumors
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancers
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or…
- Trial name
- NCT06130254
- Testing
- Adagrasib, Olaparib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor Cancer
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
GH55 Capsule is a novel, highly selective small molecule dual mechanism ERK1/2 inhibitor. GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.
- Trial name
- NCT07446725
- Testing
- Phase I dose escalation, Phase I: Dose Expansion, phase II
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
ADVANCED SOLID TUMORS
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors
- Trial name
- NCT00877474
- Testing
- PM01183
- Where
- 2 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- PharmaMar
Advanced Solid Tumors
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days, to adult patients with advanced solid…
- Trial name
- NCT00410358
- Testing
- Gimatecan
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Solid Cancers, Radiotherapy
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lattice radiation therapy (LRT) is a spatially fractionated radiotherapy technique that creates alternating high - and low - dose areas within a tumor to enhance local control and reduce toxicity to surrounding tissues.
- Conditions
- Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
- Trial name
- SFRT-IM-P2 (NCT07058948)
- Testing
- lattice radiation therapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety and tolerability of the combination of neratinib plus paclitaxel, trastuzumab and pertuzumab to determine the recommended Phase…
- Trial name
- NCT02593708
- Testing
- Neratinib, Paclitaxel, Pertuzumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michelle Melisko
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Solid Tumor, Non-small Cell Lung Cancer
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT05780307
- Testing
- IMM2520
- Where
- China
- Volunteers
- 48 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other…
- Conditions
- Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT04233567
- Testing
- Infigratinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sameek Roychowdhury
Advanced Solid Cancers
Study of SC-102 in Patients With Advanced Solid Tumors
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
- Trial name
- NCT06710158
- Testing
- SC-102
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
Solid Tumor, Adult
Advanced or Recurrent Solid Tumors Treated With SHetA2
The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.
- Trial name
- Okgyn1 (NCT04928508)
- Testing
- OK-1
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Solid Tumors, Advanced Cancer
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received chemotherapy.
- Trial name
- NCT00147225
- Testing
- AMG 531, Carboplatin, Adriamycin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer.
- Trial name
- NCT04752215
- Testing
- BI 765049, ezabenlimab
- Where
- 14 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Malignant Solid Tumours
A Study of RT023 in Patients With Advanced Solid Tumors
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of RT023 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT07797426
- Testing
- RT023
- Volunteers
- 318 people
- Sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity
- Trial name
- NCT04021043
- Testing
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Tumor
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
- Trial name
- NCT06592417
- Testing
- JSKN016 injection
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd